

13. (newly added) A method according to claim 1 in which the bisphosphonate is selected from the following compounds or a pharmaceutically acceptable salt thereof, or any hydrate thereof: 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxybutane-1,1-diphosphonic acid, 1-hydroxy-ethidene-bisphosphonic acid, 1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid, ibandronic acid, 6-amino-1-hydroxyhexane-1,1-diphosphonic acid, 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, 1-(4-chlorophenylthio) methane-1,1-diphosphonic acid, 3[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid and 1,1-dichloromethane-1,1-diphosphonic acid.

14. (newly added) A method according to claim 1 wherein the bisphosphonate is pamidronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

15. (newly added) A method according to claim 1 wherein the bisphosphonate is zoledronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

16. (newly added) A method of inhibiting basic fibroblast growth factor induced angiogenesis, which comprises administering an effective amount of zoledronic acid or a pharmaceutically acceptable salt or a hydrate thereof.

17. (newly added) A method of inhibiting angiogenesis, which comprises administering an effective amount of a bisphosphonate compound or a pharmaceutically acceptable salt thereof or a hydrate thereof in combination with a vascular endothelial growth factor inhibitor.

18. (newly added) A method of claim 17 wherein the bisphosphonate compound is zoledronic acid or a pharmaceutically acceptable salt thereof or a hydrate thereof.

STATUS OF THE CLAIMS

Claims 1-10 are cancelled.

New claims 11-18 are added.

Claims 2, 3, 4, 5, 7, 9 and 10 were rejected under 35 USC 112, second paragraph.

Claims 2 and 3 were rejected under 35 USC 101.

Claims 1-8 were rejected under 35 USC 102(b) over Katdare.

Claims 1-8 were rejected under 35 USC 102(e) over Reszka et al.

Claims 9-10 were rejected under 35 USC 103(a) over Reszka et al.

Claims 11-18 are here presented for reconsideration.

REMARKS

Claims 11-15 are supported by the original claims and by the disclosure at page 3, third full paragraph. Claims 16-18 are supported by the disclosure at the last two paragraphs on page 7 of the specification.

Applicants submit that the claims here presented overcome all of the rejections under 35 USC 112, second paragraph. Accordingly, Applicants request withdrawal of the rejections.

Applicants further submit that the claims here presented overcome the rejection of claims 2 and 3 under 35 USC 101. Accordingly, Applicants request withdrawal of the rejection.

Claims 1-8 were rejected under 35 USC 102(b) over Katdare (WO 95/2967). Applicants request reconsideration and withdrawal of the rejection based on the following discussion.